Discover
ALDX
Aldeyra Therapeutics, Inc.
2.43
2 x 1.78
2 x 2.72
bid
ask
+
0.30
14.08%
2 @ 05:36 AM
2.43 +0.00 (0.00%)
| Ytd | -53.09% | |
| 1y | -38.17% |
2.10
day range
2.53
1.07
52 week range
6.17
| Open | 2.13 | Prev Close | 2.13 | Low | 2.10 | High | 2.53 | Mkt Cap | 146.58M |
| Vol | 3.41M | Avg Vol | 1.40M | EPS | -0.45 | P/E | N/A | Forward P/E | -7.80 |
| Beta | 1.43 | Short Ratio | 6.19 | Inst. Own | 62.19% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 1.74 | 200-d Avg | 3.83 | 1yr Est | 10.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-07 | 2024-09 | -0.25 | -0.25 | N/A | N/A |
| 2024-10-03 | 2024-06 | -0.21 | N/A | N/A | N/A |
| 2024-05-02 | 2024-03 | -0.08 | -0.14 | -0.06 | -75.00% |
| 2024-03-07 | 2023-12 | -0.21 | -0.08 | 0.13 | 61.90% |
| 2023-11-03 | 2023-09 | 0 | -0.14 | N/A | N/A |
| 2023-08-03 | 2023-06 | -0.31 | -0.15 | 0.16 | 51.61% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-08-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-02 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-06 | Oppenheimer | Upgrade | Outperform | Outperform |
| 2024-05-06 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-04-03 | Oppenheimer | Upgrade | Perform | Outperform |
| 2023-10-17 | Citigroup | Upgrade | Buy | Buy |
Profile
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-03-11 | BRADY TODD C | Chief Executive Officer | 1.47M | Sale |
| 2023-06-26 | BRONSTEIN BEN | Director | 28.25K | Conversion of Exercise of derivative security |
| 2024-08-11 | GREENBERG BRUCE | Chief Financial Officer | 126.38K | Sale |
| 2024-08-11 | MACHATHA STEPHEN | Officer | 236.77K | Sale |
| 2023-04-11 | MILLER-RICH NANCY | Director | 922.00 | Purchase |
| 2024-04-04 | PERCEPTIVE ADVISORS L L C | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Perceptive Advisors Llc | 9.28M | 44.11M | 15.58% |
| 2024-09-29 | Knoll Capital Management, LLC | 5.48M | 26.04M | 9.19% |
| 2024-09-29 | Vanguard Group Inc | 3.76M | 17.88M | 6.32% |
| 2024-09-29 | Blackrock Inc. | 3.73M | 17.76M | 6.27% |
| 2024-09-29 | Kennedy Capital Management, Inc. | 1.88M | 8.94M | 3.16% |
| 2024-09-29 | Geode Capital Management, LLC | 1.11M | 5.30M | 1.87% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 1.76M | 8.36M | 2.95% |
| 2024-10-30 | iShares Russell 2000 ETF | 1.30M | 6.16M | 2.18% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 697.57K | 3.32M | 1.17% |
| 2024-07-30 | Vanguard Explorer Fund, Inc. | 680.00K | 3.23M | 1.14% |
| 2024-10-30 | Invesco ETF Tr II-Invesco Dorsey Wright SmallCap Momentum ETF | 635.91K | 3.02M | 1.07% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 510.13K | 2.43M | 0.86% |